Adenosine derivatives and pharmaceutical composition thereof

Details Adenosine derivatives and pharmaceutical composition thereof Adenosine derivatives and pharmaceutical composition thereof

1992-12-28

2001-02-27

Rollins, John W. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S027630, C536S027230, C536S027620

Reissue Patent

active

RE037077

ABSTRACT:

This is a Reissue of Ser. No.
07
/
462
,
246
, filed Jan.
9
,
1990
, U.S. Pat. No.
4
,
985
,
409
.
BACKGROUND OF THE INVENTION
The present invention relates to novel adenosine derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as an active ingredient.
Hypertension is one of the most serious risk factors causing cerebral apoplexy and cardiopathy which are included in the major causes of death. Thus various antihypertensive agents such as diuretics, sympathetic depressant drugs, direct-acting vasodilators, calcium antagonists or angiotensin antagonists have been developed and used for treatment of hypertension. However, for example, side effects such as bradycardia causing various symptoms such as tiredness, depression of activity, disturbance of cerebral circulation or cerebral ischemia are sometimes observed under the treatment with sympathetic depressant drugs. Therefore, the developments of antihypertensive agents having greater safety and effectiveness are desired. As a result of investigations for orally administrable antihypertensive compounds, the inventors have found adenosine derivatives having vasodilatively hypotensive effect.
SUMMARY OF THE INVENTION
An object of the present invention is to provide novel adenosine derivatives and pharmaceutically acceptable salts thereof having an excellent antihypertensive effect. Another object of the present invention is to provide pharmaceutical compositions containing these adenosine derivatives or pharmaceutically acceptable salts thereof as an active ingredient.


REFERENCES:
patent: 3471472 (1969-10-01), Thiel et al.
patent: 3838147 (1974-09-01), Pohlke et al.
patent: 3845035 (1974-10-01), Kampe et al.
patent: 3922261 (1975-11-01), Pohlke et al.
patent: 4501735 (1985-02-01), Trivedi et al.
patent: 4614732 (1986-09-01), Hamilton et al.
patent: 4616003 (1986-10-01), Hamilton et al.
patent: 4626526 (1986-12-01), Bristol
patent: 4657897 (1987-04-01), Bristol et al.
patent: 4657898 (1987-04-01), Bristol et al.
patent: 4663313 (1987-05-01), Bristol et al.
patent: 4683223 (1987-07-01), Trivedi
patent: 4791103 (1988-12-01), Trivedi et al.
patent: 4837207 (1989-06-01), Trivedi
patent: 4843066 (1989-06-01), Yamada et al.
patent: 4985409 (1991-01-01), Yamada et al.
patent: 0269574 (1988-06-01), None
Goodman, L., “Chemical Syntheses and Transformations of Nucleosides,” Ch. 2 inBasic Principles in Nucleic Acid Chemistry,vol. 1, Ts'o (ed.), Academic Press, New York, 1974, pp. 93 and 144.
Kikugawa et al., “Platelet Aggregation Inhibitors. 4. N6-Substituted Adenosines,”J. Medicinal Chem.,16(4), 358-364 (1973).
Robins et al., “Sugar Modified N6-(3-Methyl-2-butenyl)adenosine Derivatives, N6-Benzyl Analogs, and Cytokinin-Related Nucleosides Cotanining Sulfur or Formycin,”Biochemistry,12(12), 2179-2187 (1973).
Goodman, “Chemical Syntheses and Transformations of Nucleosides”, in Basic Principles in Nucleic Acid Chemistry, P.O.P.Ts'O ed., Academic Press, New York, 1974, see p. 144.
Kikugawa et al., J. Med. Chem., 16(4), 358-364 (1973).

Affiliated with

Also associated with

Rating

Adenosine derivatives and pharmaceutical composition thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adenosine derivatives and pharmaceutical composition thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenosine derivatives and pharmaceutical composition thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2567466